Cogent Biosciences Stock 346% Surge Fueled by New Stake
A Phase 3 breakthrough unleashed a dramatic move in Cogent Biosciences. A large fund followed with a sizable stake, s...
Identify the ideal low-cost index funds for retirement using transparent criteria and performance benchmarks to guide your choices.
27,037 articlesA Phase 3 breakthrough unleashed a dramatic move in Cogent Biosciences. A large fund followed with a sizable stake, s...
When a CEO sells a large block of stock, investors take notice. This article breaks down Ingredion's recent insider m...
Two pharma giants, two very different growth stories. This guide breaks down why Eli Lilly might be the best growth s...
A single fund's exit from Klaviyo set off a ripple effect that shaved a chunk from the stock after earnings. This art...
As markets digest AI hype, Synopsys faces a potential growth trap: strong licensing revenue amid squeezed margins and...
When a tech titan steps into AI, markets listen. This article explains why apple just joined revolution could reshape...
NVIDIA helped turn early bets into life-changing gains. But can it keep delivering millionaire-maker returns? This pr...
When a CEO sells stock, it invites questions. This guide breaks down Zoom's sold company stock, what it signals about...
Spotting a strong real estate market isn’t guesswork. By watching a few proven metrics that matter: spot—rent growth,...
Analysts issue fresh calls on Block, CrowdStrike, Fortinet, and other tech names as markets digest rising yields and ...
When a trusted income vehicle slumps by half, the question isn’t just about yield—it’s about safety, value, and the b...
A sudden 47% rise in Structure Therapeutics stock has traders buzzing while a major fund exits a multi-million dollar...